Cassiopeia Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 12-12-2024
- Paid Up Capital ₹ 0.45 M
as on 12-12-2024
- Company Age 11 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2017)
- Profit 29.79%
(FY 2017)
- Net Worth -99.69%
(FY 2017)
- Total Assets -0.28%
(FY 2017)
About Cassiopeia Pharmaceuticals
The Corporate was formerly known as Georgian Diagnostics Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.45 M, as per Ministry of Corporate Affairs (MCA) records.
Virendra Kumar, Chandra Singh, Devendra Yadav, and Five other members serve as directors at the Company.
- CIN/LLPIN
U51100UP2013PTC058713
- Company No.
058713
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jul 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Cassiopeia Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Virendra Kumar  | Managing Director | 30-Jul-2013 | Current |
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Chandra Singh | Director | 22-Feb-2021 | Current |
| Devendra Yadav | Director | 22-Feb-2021 | Current |
| Yadvendra Chaubey | Director | 01-Mar-2021 | Current |
| Anantsheel Chaudhary | Director | 01-Mar-2021 | Current |
| Manish Tandon | Director | 01-Mar-2021 | Current |
| Brijesh Singh | Director | 22-Feb-2021 | Current |
Financial Performance of Cassiopeia Pharmaceuticals.
Cassiopeia Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 29.79% increase in profit. The company's net worth observed a substantial decline by a decrease of 99.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Cassiopeia Pharmaceuticals?
In 2017, Cassiopeia Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cassiopeia Pharmaceuticals?
Unlock and access historical data on people associated with Cassiopeia Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cassiopeia Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cassiopeia Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
